NEW DELHI, May 1: As India on Saturday received the first consignment of Russia’s Sputnik V COVID-19 vaccine, the Pune-based Serum Institute of India claimed to be planning to expand its production capacity outside India also to meet the rising demand for Corona vaccines.
In an interview to a London newspaper, the SII CEO Adar Poonawalla also spoke out about the pressure he was under over the production of COVID-19 vaccines to meet the ever-increasing demand in India as the country battles a devastating second wave of the coronavirus pandemic.
In his first comments since he was provided with ‘Y’ category security by the Indian government earlier this week, Poonawalla said he was receiving aggressive calls from some of the most powerful people in India, demanding supplies of Covishield — the Oxford/AstraZeneca COVID-19 vaccine that the SII is producing in India.
That pressure is largely behind his decision to fly into London to be with his wife and children, the 40-year-old entrepreneur said.
“I’m staying here (London) an extended time because I don’t want to go back to that situation. Everything falls on my shoulders but I can’t do it alone…I don’t want to be in a situation where you are just trying to do your job, and just because you can’t supply the needs of X, Y or Z you really don’t want to guess what they are going to do,” Poonawalla said.
“The level of expectation and aggression is really unprecedented. It’s overwhelming. Everyone feels they should get the vaccine. They can’t understand why anyone else should get it before them,” he said.
He indicated that his move to London was also linked to business plans to expand vaccine manufacturing to countries outside India, which may include the likes of the UK.
“There’s going to be an announcement in the next few days,” he said. According to the newspaper, by the time the Oxford/AstraZeneca vaccine was approved in January this year, the Serum Institute of India had increased its annual production capacity from 1.5 to 2.5 billion doses at a cost of $800 million, and stockpiled 50 million doses of Covishield.
The company began exporting to 68 countries, including Britain, as India seemed to have been over the worse, until the situation worsened in recent weeks.
“We’re really gasping for all the help we can get,” Poonawalla said. “I don’t think even God could have forecast it was going to get this bad,” he said.
On the charge of profiteering as the cost of Covishield was recently hiked, he termed it as “totally incorrect” and added that Covishield will still be “the most affordable vaccine on the planet” even at a higher price.
“We have done the best we can without cutting corners or doing anything wrong or profiteering. I’ll wait for history to judge,” he said.
“I’ve always had this sense of responsibility to India and the world because of the vaccines we were making, but never have we made a vaccine so needed in terms of saving lives,” he added.
Meanwhile, the Central Board of Indirect Taxes and Customs (CBIC) said India received the first consignment of Russia-made Sputnik V vaccine. The CBIC in a tweet said Hyderabad customs expedited the clearance of the COVID-19 vaccine imported from Russia.
“Hyderabad Customs, @cgstcushyd facilitated expeditious clearance of #SputnikV Vaccine imported from Russia,” the CBIC tweeted.
Finance Minister Nirmala Sitharaman in a tweet said: “Appropriate timely response @cgstcushyd. Need of the hour.”
The government had last month allowed emergency use of Sputnik V vaccine. On August 11, 2020, Russia became the world’s first country to register a coronavirus vaccine, dubbed as Sputnik V.
Following that, in September, Dr Reddy’s Laboratories and Russian Direct Investment Fund (RDIF) entered into a partnership to conduct clinical trials of Sputnik V, which is developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.
Dr Reddy’s Laboratories has already received approval from the Indian drug regulator for restricted emergency use of COVID-19 vaccine Sputnik V.
(Manas Dasgupta)
